Rosetta Genomics, Ltd. (NASDAQ: ROSG) leverages an integrative research platform to develop and commercialize a full range of microRNA-based molecular diagnostics and address critical needs in cancer and other disease areas. Building on its proprietary platform technologies and a strong IP portfolio, the company is working to solve unmet medical needs and improve the lives of patients through a proven combination of diagnostic expertise and therapeutic innovations.

The company’s current product pipeline includes an assortment of unique diagnostic tests for a collection of medical conditions – including thyroid neoplasia, heart failure, kidney rejection and Alzheimer’s disease. In recent months, Rosetta has worked to build on this pipeline and expand its presence in the industry, most notably through the acquisition of PersonalizeDx in April. PersonalizeDx is a rapidly growing molecular diagnostics and services company serving community-based pathologists, urologists, oncologists and other reference laboratories across the United States.

“The acquisition of PersonalizeDx will have wide-ranging, positive financial, commercial, operational and pipeline impact on Rosetta Genomics, and brings with it exceptional talent to complement the industry-leading team at Rosetta Genomics,” stated Kenneth A. Berlin, president and chief executive officer of Rosetta, in a recent news release. “In joining forces with PersonalizeDx, Rosetta Genomics will gain critically important commercial and revenue scale in the marketplace for oncology diagnostics.”

In May, Rosetta built on the momentum gained from its acquisition by releasing OncoGxOne™, the company’s next-generation sequencing panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. Moving forward, OncoGxOne™ will compete with currently available genomic profiling offerings through next-generation sequencing platforms that can identify potentially actionable cancer-driving mutations, which can be targeted by specific therapies.

“We look forward to a successful commercial launch for OncoGxOne™ with our recently-expanded sales force and expect that over time it will become an important contributor to our revenues,” concluded Berlin.

Rosetta’s recent efforts have strategically positioned the company to realize significant increases in revenue in the coming years. Based on PersonalizeDx’s 2014 revenue, which was $6.9 million, the company has modified its financial model, leading to forecast revenue of $18.5 million in 2016. For prospective investors, this potential growth could provide the opportunity for significant returns in the future.

For more information, visit www.rosettagenomics.com

Soul and Vibe Interactive, Inc. (OTCQB: SOUL) is an innovative video and computer games company focused on developing and publishing standout games. The company specializes in the creation of original intellectual property (IP) and has extensive experience licensing world-renowned brands from influential companies, including General Mills (GIS) and Deere & Company (DE). SOUL’s proven business model centers on multi-platform support, allowing the company to market licensed-brand and original IP-based games that can be played on consoles, mobile devices, and personal computers.

According to a report by PricewaterhouseCoopers, consumer spending on console, mobile and personal computer gaming software topped $56 billion in 2010, and gaming industry revenue is projected to reach $82 billion this year. Despite the overall maturity of the gaming industry’s distribution and marketing efforts in retail settings, digital distribution is forcing the market to evolve, putting SOUL in a strong position to capitalize moving forward. Through partnerships with some of the world’s most technically sophisticated software developers, the company is in a strong position to increase market share through the creation and licensing of engaging, highly accessible and affordable games and entertainment experiences.

In April, SOUL announced the latest addition to its IP portfolio, SirVival, a fast-paced adventure game. In keeping with the company’s multi-platform strategy, the game will be released on Apple’s App Store, Google Play, Amazon, Microsoft Store Marketplace and Facebook. Earlier this month, the company continued efforts to grow brand recognition and created an additional channel to realize sustainable returns through the announcement of Soul and Vibe Music, a publishing label through which music singles and soundtracks will be released. Soul and Vibe Music is expected to be released via digital download on iTunes, Spotify, Google Play, Amazon, Rdio, Deezer, Tidal, YouTube Music Key, Beats/MediaNet and more.

“Soul and Vibe is a name that lends itself to a wide variety of entertainment mediums,” Peter Anthony Chiodo, president and chief executive officer of SOUL, stated in a news release. “While we work as a team to expand our portfolio of published content, it makes sense for us to separately leverage select elements of that content in unique ways so it can potentially expand monetization opportunities for the company.”

Moving forward, SOUL will look to continue expanding its presence in the gaming industry through strategic licensing agreements and the creation and utilization of IP. For prospective investors, the company’s continued progress toward the launch of SirVival makes it an intriguing option to consider in the months to come.

For more information, visit www.soulandvibe.com

Ohr Pharmaceutical is an ophthalmology research and development company. Its lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored phase II clinical trials for various back-of-the-eye diseases, including wet age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy. The company’s second product, OHR/AVR118, is designed to treat cancer cachexia, which is commonly known as wasting syndrome. Through these two candidates, Ohr’s product pipeline offers a new ray of hope to patients suffering from these devastating diseases.

Unlike current wet AMD treatment options, which are administered via injection directly into the eye, Ohr’s innovative Squalamine formulation is designed for self-administration, eliminating the need for painful intravitreal injections and providing a significant cost advantage, as compared to the current standards of care. According to a report by the National Eye Institute, wet AMD is a common eye condition and a leading cause of vision loss among people aged 50 and older, affecting over 1.75 million patients in the United States alone. Through the development of Squalamine, Ohr could effectively revolutionize the standard treatment option for this condition, creating a formidable platform to realize significant growth in the ophthalmology market.

In addition to Squalamine, Ohr is addressing a vastly underserved market through the continued development of OHR/AVR118 for the treatment of cancer cachexia. Cancer cachexia is a severe wasting disorder characterized by a significant loss of appetite, weight loss, fatigue, weakness and muscle atrophy. Currently, there is no FDA approved drug for the treatment of this debilitating condition, providing Ohr with another opportunity to realize sustainable increases in shareholder returns.

With a product pipeline including two unique drug candidates in four distinctive indications currently undergoing phase II clinical trials, Ohr is continuing to set the stage for rapid increases in market share in the years to come. For prospective investors, this progress makes Ohr an intriguing option moving forward.

For more information, visit www.ohrpharmaceutical.com

Vycor Medical, Inc. (OTCQB: VYCO) is changing and improving lives every day by providing the medical community with innovative and superior surgical and therapeutic tools, including a growing portfolio of FDA-cleared medical solutions. The company currently operates two unique but complementary business units, Vycor Medical and NovaVision, which adopt a minimally or non-invasive approach to a collection of underserved medical applications.

Through its Vycor Medical unit, the company designs, develops and markets the ViewSite Brain Access System (VBAS), a proprietary suite of clear cylindrical disposable devices used to gain access to specific neurological sites, such as tumors within the brain. Vycor’s innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community.

In recent months, the company has made significant headway toward expanding VBAS’s presence within the medical industry, increasing the number of U.S. hospitals for which the system is approved to more than 190 during the first quarter of 2015. In large part, this growth has come as a result of increasingly prevalent scientific data on the system. According to a recently released study on VBAS published by surgeons from Sapporo Medical University in Japan, the suite is believed to provide a safer, more reliable, and less invasive method for the treatment of deep-seated brain tumors.

“We continue to make good progress with our VBAS product and the new studies we are anticipating this year together with the launch of additional products makes me confident this will translate into increased VBAS penetration and greater market acceptance during the course of this year,” stated Peter Zachariou, chief executive officer of Vycor, in a recent news release.

Through its NovaVision unit, Vycor targets a substantial and largely unaddressed market of people who have lost their sight as a result of stroke or traumatic brain injury. The company’s family of therapies, which are clinically supported by decades of scientific research, both restore and help to compensate for lost vision.

NovaVision’s unique product offerings have gained significant industry traction in recent months. Late in 2014, the company received receipt of approval from HealthSouth to offer the NovaVision VIDIT diagnostic device, and, earlier this month, Vycor continued on this success by partnering with HealthSouth for a second time to make available its NeuroEyeCoach Professional Center therapy program. These two agreements provide the company with access to a potentially massive source of patients, as HealthSouth is one of the largest providers of post-acute healthcare services in the country.

“NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on our strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering from visual impairment following neurological damage,” continued Zachariou.

Moving forward, Vycor is in an increasingly strong position to realize enhanced returns. Despite a slim decrease in reported year-over-year revenue for the first quarter of 2015, the company’s recently announced agreements with HealthSouth, as well as expanding product approval rates for the VBAS, make Vycor an intriguing option for prospective investors in the months to come.

For more information, visit www.vycormedical.com

Pure Hospitality Solutions, in an effort to continue building shareholder confidence, recently released a collection of site design snapshots for its upcoming Central American-Caribbean online travel hub, Oveedia.

“[W]e are currently at a stage where testing will soon begin and an early launch is likely,” Melvin Pereira, president and chief executive officer of Pure, stated in a news release. “Our programmers are working tirelessly to ensure Oveedia’s launch is not only accelerated, but that an ultra-friendly user experience is achieved by front-end consumers.”

With the snapshots, Pure is providing shareholders with a glimpse into the style, functionality and design of the Oveedia platform. Along with two unique desktop versions of its design, the preview also includes both tablet and mobile design snapshots, highlighting the quantifiable progress of Pure in recent months.

“We are exploring two differently designed, ultra-responsive versions, all shown as the platform will appear on a desktop, smartphone or tablet,” continued Pereira. “We are on our way to having one of the most incredible assets in the history of our organization.”

In May, Pure took a significant step toward increasing the potential value of Oveedia by becoming a member of the Sabre Travel Network. Through this agreement, the company gained access to a $7 billion booking network, including more than 125,000 hotels, 400 airlines, 16 cruise lines and 25 car rental selections. In addition to its partnership with Sabre, Pure has also made major strides toward a sustainable presence in the growing Central American-Caribbean travel industry through the continued expansion of its standalone travel network. Last week, the company added Jaco Tour Company to the fold, and expansion to approximately 300 hotels and travel-related businesses is expected by the end of the year.

According to a report by Amadeus, the online travel agency segment in the Latin American market is expected to account for $98.5 billion in 2016, providing Pure with the opportunity to realize rapid increases in market share following Oveedia’s initial release. Integration with the Sabre Travel Network, as well as continued expansion of Pure’s standalone region-specific travel network, should make Oveedia a strong acquisition target for larger, globally dominant OTAs – including Expedia and Priceline – in the years to come. For prospective shareholders, the impending launch of Oveedia makes Pure an intriguing investment opportunity moving forward.

For more information on Pure Hospitality Solutions, visit www.purenow.solutions

Let us hear your thoughts: Oriens Travel and Hotel Management Corp. Message Board

Baltimore, Maryland-based View Systems provides state-of-the-art security technology products for the growing $100 billion a year security industry. The company’s solutions are applicable for a wide range of entities in need of security solutions, including correctional institutions, government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

ViewScan, the company’s flagship product, is an advanced walk-through Concealed Weapons Detection System (CWD) that utilizes highly sensitive, completely passive sensor technology that drastically simplifies the process of discriminating suspicious items from harmless ones. The technology accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles.

While highly accurate, the system does not emit electro-magnetic fields, radiation, millimeter waves or X-rays, which means it’s safe for pacemakers, implants and pregnant women. In addition, ViewScan has been designated by the U.S Department of Homeland Security as a Qualified Anti-Terrorism Technology (QATT).

Due to a high demand from the correctional industry, View Systems added the LAW Handheld Metal Detector to its Weapon Detection Devices product line. The company’s NEW Law is a high-sensitivity metal detector that features rapid speed and high definition technology that makes it highly complementary to the ViewScan.

View Systems’ first response remote video transmission system is utilized in areas where hazardous materials have been exposed. The solution is small enough to be worn on a belt, helmet or vest, and it transmits conventional video or infrared imagery to the command post, making it ideal for law enforcement SWAT teams, Fire Rescue units and HAZMAT team operations.

The company is constantly conducting research and development to ensure its technologies evolve with the changing security environment. Leading this charge is a senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

Milestone Scientific, Inc. (NYSE MKT: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Since 1995, the company’s commitment to advancing the science of computer-controlled drug delivery technologies has helped it earn global distinction as an industry leader in the fields of medicine and dentistry. Milestone’s patented CompuFlo® system and DPS Dynamic Pressure Sensing® technology are revolutionary tools that enable practitioners to accomplish a collection of tasks that exceed the capabilities of the 150 year-old manual syringe.

The CompuFlo® system provides a safer, painless delivery alternative for all types of subcutaneous injections in the medical practice. Utilizing Milestone’s proprietary pressure sensing technology, the system offers safe, effective feedback to assist healthcare providers in identifying a specific anatomic location. In addition to more accurate injections, the platform is capable of documenting injection events to provide more reliable recordkeeping for both patients and healthcare providers.

In recent months, Milestone, through its Epidural & IA subsidiary, has turned its attention towards a clinical trial to verify the placement of the epidural needle tip in the lumbar epidural space. Since receiving FDA approval in March, the company has opened enrollment for clinical testing, aiming to enroll up to 400 patients in the trial at four sites throughout the United States.

“A major focus of the Company in 2015 is commercializing the first medical applications of our technology platform, including those licensed by our Epidural & IA Subsidiary,” stated Leonard Osser, Chief Executive Officer of Milestone. “Our Epidural & IA Subsidiary has been in negotiations with distributors in a number of countries… [and] recently signed its first distribution agreement with TRIMED SP.z.o.o., one of the largest distributors of diagnostic equipment in Poland.”

In the first quarter of 2015, Milestone made took major steps towards realizing sustainable growth by signing a letter of intent with MILA International for marketing, distribution and commercialization of an anesthetic delivery instrument for maxillary nerve block procedures in horses. Through this agreement, the company will gain access to the $24 billion global animal health industry, providing an additional platform for continued expansion.

“Our strategy is to collaborate on the development, commercialization and distribution of an anesthetic delivery instrument… [for which] MILA will be responsible for marketing and distribution and Milestone will manufacture product,” continued Osser.

For prospective investors, the company’s continued dedication to innovation and an increasingly broad collection of target markets provide the opportunity to realize sustainable returns in the future.

For more information, visit www.milesci.com

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) is an oil and gas Exploration and Production company with a primary focus on acquisition and development of highly profitable domestic oil fields. Based in Plano, Texas, the company currently holds interests in Texas, Kansas and Oklahoma, providing access to established plays including the Eagle Ford, Mississippian and Hunton. Torchlight’s focus on highly probable and profitable drilling and working interest programs that feature proven and bookable reserves has allowed the company to strategically position itself for tremendous growth moving forward.

Among Torchlight’s most promising projects is the Hunton Play, which is located in Logan and Kingfisher Counties, Oklahoma. The company’s interest in the area is divided into two unique projects: The Cimarron Project and The Chisholm Trail Project, of which Torchlight owns a 15 percent and 15.3 percent working interest, respectively. Combined, the two nearly contiguous projects cover an area of approximately 8,800 acres and fit well into the company’s strategic plan of leveraging new technologies to capitalize on established plays.

In September 2014, Torchlight acquired a 100 percent working interest in its 172,000 acre Orogrande Basin prospect. Through this agreement, the company received a five-year lease on the property that also carries additional five-year extension provisions. In March, Torchlight took a major step towards capitalizing on this interest by beginning drilling operations on its first well on the property. In May, the company built on this progress through the announcement that it had reached total depth on its initial test well.

“We are encouraged by the prospect that this well provides Torchlight shareholders,” stated Will McAndrew, Chief Operating Officer of Torchlight. “Although early in the process, we are very encouraged by what we have encountered while drilling.”

In recent weeks, Torchlight has turned its attention towards investment in order to gain the flexibility required to maximize the value of its current projects. Earlier this week, the company announced that it had closed on the sale of nearly $10 million in Series A Convertible Preferred Stock. This move allowed the company to pay off its senior debt and prepare for continued growth into the future.

“We are thrilled to get this transaction completed with favorable terms and in the current market environment,” stated John Brda, Chief Executive Officer of Torchlight. “This new capital allows us to fulfill the commitments made to our stakeholders and further the development of our asset base.”

For prospective investors, Torchlight’s recent moves have made it an intriguing option in the coming months. As the company continues to develop its Orogrande Project and expand its production capabilities, Torchlight could be in a strong position to realize sustainable returns for the foreseeable future.

For more information, visit www.torchlightenergy.com

Transition Therapeutics, Inc. (NASDAQ: TTHI) is a biopharmaceutical company developing novel therapeutics for disease indications with large markets. The company’s leading drug candidate, ELND005, is designed to treat the agitation and aggression associated with Alzheimer’s disease and Down syndrome. Additionally, Transition is developing TT401, a metabolic drug candidate formulated to treat type 2 diabetes and its accompanying obesity. Through the continued development and clinical testing of these two products, the company is addressing medical markets that are currently underserved.

According to the Alzheimer’s Association, an estimated 5.3 million Americans of all ages currently suffer from Alzheimer’s disease. Among those individuals, up to 60 percent will develop behavioral symptoms, such as agitation or aggression, over the course of their lives. Transition is making progress towards improving the comfort of those affected by these symptoms through the continued development of ELND005. In a completed Phase II study, the drug candidate appeared to decrease the emergence and severity of these neuropsychiatric symptoms by reducing myo-inositol levels in the brain.

In March, Transition took a major step towards the commercialization of its leading drug candidate through the completion of absorption-metabolism-excretion (AME) and renal clearance studies. These trials are required by the United States Food and Drug Administration for the approval of nearly all drugs in development. In both cases, ELND005 demonstrated good safety and tolerability, clearing the path for more advanced clinical trials moving forward.

The company’s product pipeline was expanded in May when Transition announced that its wholly-owned subsidiary had acquired exclusive worldwide licensing rights to TT701, a selective androgen receptor modulator that’s been shown to significantly increase lean body mass and muscle strength in male subjects.

“The safety and efficacy profile of TT701 creates a number of development opportunities,” stated Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition. “[The company] will initiate development and manufacturing activities to enable the start of a Phase 2 study in the coming months.”

Transition is expected to continue making progress towards the commercialization of its robust product pipeline moving forward. With Phase II clinical trials for three drug candidates in four unique indications ongoing, completed or upcoming, the company appears to be closing in on a significant opportunity to realize sustainable returns in the years to come.

For more information, visit www.transitiontherapeutics.com

Pure Hospitality Solutions, Inc. (OTC: PNOW) announced that it had teamed with Costa Rica-based Jaco Tour Company, allowing the company’s upcoming OTA, the Oveedia Travel Network, to officially add excursions to its growing database of reservation options.

“Today marks another major milestone for PURE, Oveedia and our reputation within the Central American-Caribbean region,” stated Melvin Pereira, President and Chief Executive Officer of Pure. “After a number of conversations and meetings, Oveedia has its first independent tour company, on-top of Sabre’s extensive database.”

Through the deal, Pure has agreed to feature the Jaco Tour Company on Oveedia’s homepage, providing travelers with access to exclusive pricing on fishing charters, transportation, local tours and day trips throughout all of Costa Rica. Moving forward, these independent offers will allow Pure to differentiate Oveedia from worldwide OTAs, further demonstrating the market for region-specific solutions in the Central American-Caribbean travel market and, potentially, increasing the end value of the Oveedia platform.

“While being a part of Sabre’s $7 Billion Travel Network family is absolutely crucial, it’s the independent hotels and companies, such as the Tango Mar and now the Jaco Tour Company, which makes Oveedia completely unique and extremely valuable,” continued Pereira. “Oveedia will have an entire region of properties and travel companies represented on its platform that are not readily listed on larger, globally known OTA’s. This, in and of itself, makes the platform extremely valuable as an acquisition target.”

Earlier this week, Pure took a major step towards the launch of its groundbreaking OTA platform by submitting the Oveedia architecture to the Sabre Travel Network. Through its partnership with Sabre, the company added more than 125,000 hotels, 400 airlines, 16 cruise lines and 25 car rental selections to its reservation database, but the importance of independent deals to the overall success of Oveedia can’t be overstated. With the early stages of the company’s three phase rollout of the network scheduled to begin in the upcoming weeks, Pure is continuing to amplify the OTAs massive potential through these region-specific partnerships.

According to a report by eMarketer, the Latin American region has led the world in terms of online travel sales growth for the better part of a decade. From 2010 to 2013, the region recorded annual growth topping 30 percent, and this rapid expansion is expected to continue in the years to come. Through the development of the Oveedia platform, Pure is positioning itself to translate this growth into sustainable returns moving forward. Look for the company to make waves in the OTA industry as it continues to expand its database of booking options, establishing Oveedia as a potentially lucrative acquisition target in the near future.

For more information on Pure Hospitality Solutions, visit www.purenow.solutions

Let us hear your thoughts: Oriens Travel and Hotel Management Corp. Message Board